Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with U.S. biotech firm Nurix Therapeutics, a deal valued at up to $2.3 billion to develop and commercialize the experimental blood cancer drug bexobrutideg. The partnership was announced on Monday, June 8, 2026.